

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
22 November 2018 (22.11.2018)



(10) International Publication Number
WO 2018/209701 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) *G01N 33/574* (2006.01)
C12N 15/13 (2006.01) *C12N 1/21* (2006.01)
A61K 39/395 (2006.01) *C12N 5/10* (2006.01)
A61P 35/00 (2006.01) *C12N 15/63* (2006.01)
A61P 37/04 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/CN2017/085134

(22) International Filing Date:

19 May 2017 (19.05.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicant: **WUXI BIOLOGICS (SHANGHAI) CO., LTD.** [CN/CN]; Pudong District, Meisheng Road 227, Shanghai 200131 (CN).

(72) Inventors: **WANG, Zhuozhi**; Shanghai Pudong, Meisheng Road 227, 10-321B, Shanghai 200131 (CN). **LI, Jing**; 11 Dunham Street, Lexington, MA 02420 (US). **GOLOBOV, Gennady**; 204 Ridgepoint Pl., Gaithersburg, MD 20878 (US). **XU, Jianqing**; Room 402, No. 37, Lane 4850, Chuansha Road, Pudong District, Shanghai 201200 (CN).

(74) Agent: **LEE AND LI - LEAVEN IPR AGENCY LTD.**; Unit 2202, Tower A, Beijing Marriott Center, No. 7, Jian Guo Men South Avenue, Beijing 100005 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: NOVEL MONOCLONAL ANTIBODIES TO CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4 (CTLA-4)

(57) Abstract: The present invention provides CTLA-4 monoclonal antibodies, particularly humanized monoclonal antibodies specifically binding to CTLA-4 with high affinity. The present invention also provides functional monoclonal antibodies cross-reactive to CTLA-4 of human, cynomolgus monkey and mouse. The present invention further provides amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. The epitopes of the antibodies are identified. Therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancers and other diseases with anti-CTLA-4 antibodies.

WO 2018/209701 A1